semaglutide and potassium Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications Two New GLP -1 Breakthroughs!
Description
Appetite begins returning
683 Zafar, A
#TaibaRare #RareMetabolicDisease #PatientAwareness #LipodystrophyAwareness #RareDisease #MetabolicHealth #WorldLipodystrophyDay #RareDisorders #ChronicIllness To view or add a comment, sign in Ashley Shoemaker, MD, MSci, of Vanderbilt Health discusses the FDA approval of setmelanotide (Imcivree), the first targeted therapy for acquired hypothalamic obesity in patients 4+ years
The views expressed are those of the authors and not necessarily those of the NIHR, the UK MRC, the UK NHS or the UK Department of Health
More value
